Project Grant R43EB029884
- The National Science Foundation (NSF) awarded a $305,000 STTR Phase I project grant to Sensvita Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a non-invasive radio frequency sensing technology for home-based monitoring of heart and lung function. The proposed system uses advanced sensing methods to measure critical physiological parameters without the need for skin contact or maintenance, improving the convenience, scalability,...
- The National Science Foundation (NSF) awarded a three-year, $449,999 Project Grant under their Engineering program (CFDA 47.041) to the University of Cincinnati to develop an implantable biosensor platform that can continuously monitor various biomarkers in the body for over a year. The project aims to create a new class of long-lasting aptamer-based sensors protected by robust porous oxide coatings, which would enable the first practical implantable monitoring system for managing chronic...
- Dynocardia Inc. received a $256,000 National Science Foundation Project Grant to advance development of a novel continuous, cuffless blood pressure monitoring device. Funded through the NSF Engineering Directorate's SBIR program, the award will support Dynocardia's efforts to address motion artifacts and enable accurate, beat-to-beat blood pressure measurements in hospital intensive care and operating room settings. Accurate 24-hour blood pressure monitoring has potential to significantly...
- Federal Project Grant Summary Actiox LLC received a $699,468 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 10, 2025, with completion targeted for October 31, 2026. The grant funds development of a wearable microneedle-based biosensor for continuous, real-time monitoring of cardiac troponin I (cTnI) in interstitial fluid. This innovative device integrates aptamer-based electrochemical...
- RCE Technologies, Inc. was awarded a $255,892 Small Business Innovation Research Phase I Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program to develop a proof-of-concept machine learning-based diagnostic system for detecting myocardial infarction and ischemia in real-time. The system aims to provide point-of-care clinical classification for heart attack cases using a novel, portable device integrating the awardee's proprietary external...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston University a $1.27 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on September 2, 2025, to develop high-speed wearable speckle contrast optical spectroscopy (SCOS) technology for cuffless blood pressure monitoring. The project, scheduled for completion by May 31, 2029, addresses the significant clinical limitation of current ambulatory blood pressure...
- The National Science Foundation awarded Integrated Medical Sensors Inc. a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel multi-analyte microsensor platform for continuous wireless monitoring applications. The grant aims to create a unique monolithic semiconductor platform capable of wirelessly monitoring multiple biochemical and physiological markers simultaneously in a sub-cubic millimeter footprint. This miniature,...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $511,798 was awarded to Kilele Health Inc. on June 15, 2022 to develop continuous diagnostic monitoring platforms beyond glucose sensing. Unlike existing enzymatic glucose sensors, the company will utilize electrochemical aptamer sensors that can rapidly measure other molecules in the body with high specificity and sensitivity. The aim is to address limitations that have...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New Jersey Institute of Technology a Project Grant of $718,678 under the Cardiovascular Diseases Research program (CFDA 93.837) to develop innovative cardiac energy harvesting technology for leadless intracardiac pacemakers. The award, effective June 1, 2026, through February 28, 2031, funds research to design advanced nanomaterials and bistable piezoelectric structures that integrate with existing...
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $374,378 to Michigan State University to develop a computational modeling framework for a miniaturized, noninvasive, wireless, luminescence-based carbon dioxide sensing wearable device. The goal is to accurately translate transcutaneous partial pressure of CO2...
INNOVATIVE, NON-INVASIVE, BATTERY-LESS, DISPOSABLE CARDIAC BIOSENSOR FOR HEMODYNAMIC MONITORING - 7. PROJECT SUMMARY/ABSTRACT THIS SBIR PHASE I PROJECT WILL DESIGN AND DEVELOP AN INNOVATIVE, MINIATURE, BATTERY-LESS, DISPOSABLE CARDIAC BIOSENSOR, TO PROVIDE EASY HOME ASSESSMENT OF HEART AND LUNG FUNCTION. THE BIOSENSOR WILL DELIVER COMPARABLE HEMODYNAMIC MEASUREMENTS TO THE GOLD STANDARD ASSESSMENTS. ECONOMIC IMPETUS HAS LED TO EARLY DISCHARGE OF COMPLEX AND ELDERLY PATIENTS WITH CARDIOVASCULAR DISEASE. OLDER ADULTS DISCHARGED FROM HOSPITALS FOLLOWING DIAGNOSES OF CONGESTIVE HEART FAILURE EXACERBATION, MYOCARDIAL INFARCTION, CORONARY ARTERY BYPASS GRAFTING SURGERY OR OTHER HIGH-RISK CARDIAC PROCEDURES ARE AT HIGHER RISK FOR RE-HOSPITALIZATIONS AND INCREASED MORTALITY RESULTING FROM GAPS IN CARE FOLLOWING HOSPITAL DISCHARGE. THE ASSESSMENT SOLUTIONS AVAILABLE FOR PATIENT MONITORING AT HOME, NAMELY, BLOOD PRESSURE, WEIGHT, ELECTROCARDIOGRAMS, HAVE NOT DEMONSTRATED REDUCTION IN READMISSION FOR ANY REASON OR DEATH OF ANY CAUSES AFTER DISCHARGE. INVASIVE IMPLANT DEVICES, SUCH AS CARDIOMEMS, HAVE DEMONSTRATED THAT HEMODYNAMIC MEASUREMENTS ALLOW MORE EFFECTIVE MANAGEMENT LEADING TO FEWER HOSPITALIZATIONS AND LOWER DEATHS. THUS, AGING ADULTS ARE IN NEED OF RELIABLE, ROBUST, SAFE (NON-INVASIVE), AND SIMPLE TECHNOLOGIES THAT CAN PROVIDE HEMODYNAMIC ASSESSMENT POST HOSPITALIZATION. THERE IS NEED FOR MEANINGFUL INTERVENTIONS THROUGH A PHONE CONSULTATION OR OUTPATIENT PRIMARY CARE VISITS THAT REDUCE RE-ADMISSIONS AND MORTALITY. USING THIS SBIRS TECHNOLOGY, IT WILL BE POSSIBLE FOR A PATIENT TO HAVE ACCESS TO GOLD STANDARD HEMODYNAMIC MEASUREMENTS, THROUGH AN INTEGRATED, WEARABLE, BATTERY-LESS, CARDIAC BIOSENSOR. THE BIOSENSOR'S DATA CAN BE READ WITH A SMART PHONE USING SECURE NEAR FIELD COMMUNICATION, ENABLING PATIENTS AND THEIR HEALTH CARE PROVIDERS TO HAVE EASY ACCESS TO THEIR HEMODYNAMIC MEASUREMENTS VIA A SMARTPHONE APPLICATION. EARLY OBJECTIVE MEASUREMENTS OF HEMODYNAMIC CHANGES WILL LEAD TO EARLY AND PROMPT OUTPATIENT INTERVENTIONS. THIS WILL IMPROVE THE QUALITY OF LIFE FOR INDIVIDUALS WITH CHRONIC CARDIOVASCULAR CONDITIONS ENABLING THEM TO REMAIN AT HOME LONGER. WE HAVE A MULTIDISCIPLINARY TEAM OF SCIENTISTS AND PRACTICE STAKEHOLDERS WHO WILL WORK TOGETHER TO DEVELOP AND TEST THE CONCEPTUAL MODEL THAT WILL BE APPLICABLE ACROSS DIVERSE PATIENT POPULATIONS. THE OVERALL GOAL OF THIS PROJECT IT TO DEMONSTRATE THAT NEW TECHNOLOGY CAN MEANINGFULLY ACCOMMODATE THE NEEDS OF OLDER ADULTS AND ADDRESS THEIR UNIQUE PROBLEMS AND CHALLENGES. FOR THE FIRST TIME THERE WILL BE A BIOSENSOR THAT TRULY ADDRESSES THE MARKET NEED OF AN UN-OBSTRUCTIVE, NON-INVASIVE, ACCURATE, ABSOLUTE AND ACTIONABLE SYSTEM FOR POST-DISCHARGE USE AT HOME. THIS WILL FACILITATE CLOSE SELF-MONITORING AND OUTPATIENT MONITORING OF OUR MOST VULNERABLE PATIENTS, WHILE MAINTAINING CLOSE SUPERVISION BY THE HEALTH CARE TEAMS. THIS BATTERY-LESS, DISPOSABLE BIOSENSOR TECHNOLOGY FOR PROVIDING IN-DEPTH HEMODYNAMICS HAS ADDITIONAL FAR REACHING BENEFITS. SUCH A DEVICE DOES NOT EXIST TODAY THUS OPENING UP NUMEROUS COMMERCIAL POSSIBILITIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 12/2/22 | ||
| Not listed | $0 | 12/2/22 | ||
| Not listed | $225.0k | 9/18/21 | ||
| Not listed | $225.0k | 9/18/21 |